Methods for Microencapsulated Porcine Islet Production

  • Masayuki Shimoda
  • Shinichi MatsumotoEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1479)


Allogeneic islet transplantation has become a viable option for the treatment of unstable type 1 diabetes; however, donor shortage and the necessity for immunosuppressive drugs are two major drawbacks of this treatment. Microencapsulated porcine islets can solve both of these drawbacks, and clinical trials have been conducted. Previous clinical trials demonstrated the safety and marginal efficacy of this treatment; therefore, it is necessary to improve its efficacy. The production of microencapsulated porcine islets consists of pancreas procurement, islet isolation, and microencapsulation. In this chapter, we describe our current methods for porcine pancreas procurement, islet isolation, and microencapsulation.

Key words

Pancreas procurement Porcine islets Microencapsulation Islet transplantation Donor shortage Type 1 diabetes 


  1. 1.
    Bartlett ST, Markmann JF, Johnson P, et al (2015) Report from IPITA-TTS opinion leaders meeting on the future of beta cell replacement. Transplantation (in press)Google Scholar
  2. 2.
    Bruni A, Gala-Lopez B, Pepper AR et al (2014) Islet cell transplantation for the treatment of type I diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes 7:211–223Google Scholar
  3. 3.
    Matsumoto S (2010) Islet cell transplantation for type 1 diabetes. J Diabetes 2:16–22CrossRefGoogle Scholar
  4. 4.
    Elliott RB, Escobar L, Tan PLJ et al (2007) Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 14:157–161CrossRefGoogle Scholar
  5. 5.
    Korbutt GS, Elliott JF, Ao Z et al (1996) Large scale isolation, growth and function of porcine neonatal islet cells. J Clin Invest 97:270–280CrossRefGoogle Scholar
  6. 6.
    Calafiore R, Basta G (2014) Clinical application of microencapsulated islets: actual prospective on progress and challenges. Adv Drug Deliv Rev 67–68:84–92CrossRefGoogle Scholar
  7. 7.
    Matsumoto S, Tan P, Baker J et al (2014) Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc 46:1992–1995CrossRefGoogle Scholar
  8. 8.
    Matsumoto S, Takita M, Chaussabel D et al (2011) Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1beta and TNF-alpha. Cell Transplant 20:1641–1647CrossRefGoogle Scholar
  9. 9.
    Matsumoto S, Noguchi H, Shimoda M et al (2010) Seven consecutive successful clinical islet isolations with pancreatic ductal injection. Cell Transplant 19:291–297CrossRefGoogle Scholar
  10. 10.
    Shimoda M, Noguchi H, Fujita Y et al (2012) Improvement of collagenase distribution with the ductal preservation for human islet isolation. Islets 4:130–137CrossRefGoogle Scholar
  11. 11.
    Qin H, Matsumoto S, Klintmalm GB et al (2011) A meta-analysis for comparison of the two-layer and university of Wisconsin pancreas preservation methods in islet isolation. Cell Transplant 20:1127–1137CrossRefGoogle Scholar
  12. 12.
    Calafiore R, Basta G, Luca G et al (2006) Standard technical procedures for microencapsulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. Transplant Proc 38:1156–1157CrossRefGoogle Scholar
  13. 13.
    Hillberg A, Kathirgamanathan K, Lam JBB et al (2013) Improving alginate-poly-L-ornithine-alginate capsule biocompatibility through genipin crosslinking. J Biomed Mater Res B Appl Biomater 101:258–268CrossRefGoogle Scholar
  14. 14.
    Kitzmann JP, Law L, Shome A et al (2012) Real-time assessment of encapsulated neonatal porcine islets prior to clinical xenotransplantation. Xenotransplantation 19:333–336CrossRefGoogle Scholar
  15. 15.
    Matsumoto S, Qualley SA, Goel S et al (2002) Effect of the two-layer (University of Wisconsin solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton isolation protocol. Transplantation 2002(74):1414–1419CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.National Center for Global Health and MedicineTokyoJapan
  2. 2.Otsuka Pharmaceutical Factory Inc.NarutoJapan

Personalised recommendations